Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16888382 | 0.93 | EEF2K (1.00) | EEF2KMEN1ALDH1A1GAAMAPT | |
| SCHEMBL20536169 | 0.93 | EEF2K (0.86) | EEF2KMEN1ALDH1A1GAAMAPT | |
| SCHEMBL16888385 | 0.86 | EEF2K (1.00) | EEF2K | |
| SCHEMBL18186043 | 0.85 | EEF2K (0.86) | EEF2KMEN1ALDH1A1GAAMAPT | |
| SCHEMBL16888388 | 0.84 | EEF2K (1.00) | EEF2KMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16888392 | 0.82 | EEF2K (1.00) | EEF2KMEN1ALDH1A1GAAMAPT | |
| SCHEMBL16888395 | 0.82 | EEF2K (1.00) | EEF2KMEN1ALDH1A1GAAMAPT | |
| SCHEMBL16888397 | 0.81 | EEF2K (1.00) | EEF2KALDH1A1GAA | |
| SCHEMBL18186040 | 0.78 | EEF2K (0.85) | EEF2K | |
| SCHEMBL16878968 | 0.77 | EEF2K (1.00) | EEF2KALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318948-A1 | Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity | LONGEVICA PHARMACEUTICALS INC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318948-A1 | Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity | LONGEVICA PHARMACEUTICALS INC (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015102752-A1 | COMPOUNDS INHIBITING EUKARYOTIC ELONGATION FACTOR 2 KINASE ACTIVITY | LONGEVICA PHARMACEUTICALS, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318948-A1 | Compounds Inhibiting Eukaryotic Elongation Factor 2 Kinase Activity | EEF2K, EIF2AK1, EIF4EBP1 | EEF2K 1/4885MEN1 2323/4885ALDH1A1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.